Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd."
Count: 41
Selected: 0
| NCT ID | Title |
|---|
| NCT04538911 | Phase I Clinical Protocol for Pre-evaluation of the Safety of BCG-PPD in Tuberculosis Patients | ||
| NCT03026972 | A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried | ||
| NCT06043388 | Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial | ||
| NCT05205096 | Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of CoronaVac | ||
| NCT06025812 | Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) | ||
| NCT05899179 | Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above | ||
| NCT04593771 | Phase I Clinical Protocol of BCG-PPD in Healthy People | ||
| NCT05198063 | ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization | ||
| NCT04852068 | A Clinical Trial of Freeze-dried Human Rabies Vaccine (Vero Cells) | ||
| NCT05895110 | To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2 | ||
| NCT05746611 | Phase IV Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein | ||
| NCT05680415 | Clinical Trial of Mica | ||
| NCT05107375 | Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine | ||
| NCT05890521 | Safety Study of COVID19 Vaccine on the Market | ||
| NCT05642078 | Quadrivalent Influenza Virus Split Vaccine | ||
| NCT05850507 | Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) | ||
| NCT05284812 | A Phase Ⅱ Clinical Trial of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) | ||
| NCT04563273 | Clinical Study of BCG Vaccine for Intradermal Injection | ||
| NCT05574985 | Recombinant Omicron-Delta COVID-19 Vaccine (CHO Cell) | ||
| NCT05109598 | Clinical Trial of Immunogenicity Bridging of a Recombinant New Coronavirus（COVID-19） Vaccine (CHO Cell) | ||
| NCT04961359 | Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old) | ||
| NCT04563533 | Clinical Trial of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) | ||
| NCT05616754 | A Trial Evaluate the Immunogenicity and Safety of Recombinant COVID-19 Omicron-Delta Variant Vaccine (CHO Cell) | ||
| NCT05198102 | ZF2001 Booster Immunization Clinical Trials of 12 Months After the Completion of Basic Immunization | ||
| NCT04239313 | A Phase Ib Study of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried (AEC/BC02) | ||
| NCT05128643 | Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell) | ||
| NCT05205083 | Immunogenicity and Safety of Booster Immunization of ZF2001 After Inoculation With Two Doses of BBIBP-CorV | ||
| NCT04646590 | A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19 | ||
| NCT05091411 | Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells) | ||
| NCT05089045 | Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity | ||
| NCT04550351 | Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old) | ||
| NCT04466085 | Clinical Study of Recombinant Novel Coronavirus Vaccine | ||
| NCT04445194 | Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine | ||
| NCT02795260 | Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy) | ||
| NCT01979900 | Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis | ||
| NCT02623556 | Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen | ||
| NCT03027154 | Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children | ||
| NCT02336542 | Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 | ||
| NCT02389322 | Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65 | ||
| NCT02329730 | Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 | ||
| NCT01999231 | Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 |
